December 26, 2024 06:57 pm (IST)
Follow us:
facebook-white sharing button
twitter-white sharing button
instagram-white sharing button
youtube-white sharing button
Anna University sexual assault case: Accused is a DMK worker, claims BJP's Annamalai | Celebrities too responsible for crowd control: Telangana CM Revanth Reddy to Telugu filmdom amid Pushpa 2 stampede row | Boat capsizes off Calangute Beach in Goa; 1 killed, 20 rescued | Canada announces change to immigration system, likely to impact Indians seeking permanent residence | Azerbaijan Airlines tragedy: 32 passengers rescued, flight attempted several emergency landing before crashing | Man sets himself on fire near Parliament building; locals, police rush him to hospital | Azerbaijan Airlines passenger plane enroute to Russia with over 70 people onboard crashes in Kazakhstan | Atishi will be arrested in fake case, claims Arvind Kejriwal after Delhi govt disowns health and women's schemes | Delhi govt departments disown Arvind Kejriwal's major poll promises, AAP chief reacts | 'Our nation will always be grateful to him': PM Modi writes article in tribute to Atal Bihari Vajpayee on his birth centenary
Image: UNI

MSN Labs launches Posaconazole (PosaOne) to treat Black fungus

| @indiablooms | May 22, 2021, at 12:21 am

Kolkata/IBNS: The drug-maker enterprise MSN Laboratories Pvt. Ltd. (MSN), introduced Posaconazole in India, under the brand name PosaOne, which is a triazole antifungal agent indicated for treating mucormycosis patients.

PosaOne contains both 100 mg delayed-release tablets & 300 mg injections. While the price of the tablet is Rs 600, the injections cost's a staggering Rs 8,500, according to The Hindu.

Many patients recovering from Covid 19 have been detected with a rare and deadly fungal infection known as mucormycosis or Black fungus. With mortality rates on the rise, accessibility of anti-fungal medication is being an unmet deficit in these testing times, MSN told.

The company officials mentioned that due to MSN’s competence in research and manufacturing of antifungal infection drugs, it is now targeting proactively to reach patients across India by ensuring the access of  PosaOne, through its distribution network & field force.

MSN has also developed the active pharmaceutical ingredient and the formulation of PosaOne in its in-house R&D and manufacturing units, company personnel informed, while also stating that the drug is approved by the Drug Controller General of India (DGCI) and matches the international quality standards.

As part of the COVID treatment range, MSN has already launched Favilow (Favipiravir) in the strengths of 200mg, 400mg & 800mg, OSELOW (Oseltamivir) as 75 mg capsules, recently, it also licensed Baridoz (Baricitinib) with Eli Lilly, MSN stated.

For availability of all COVID Drugs from MSN, patients can contact MSN COVID Helpline @ 91005 91030 or email customercare@msnlabs.com for further assistance.

Support Our Journalism

We cannot do without you.. your contribution supports unbiased journalism

IBNS is not driven by any ism- not wokeism, not racism, not skewed secularism, not hyper right-wing or left liberal ideals, nor by any hardline religious beliefs or hyper nationalism. We want to serve you good old objective news, as they are. We do not judge or preach. We let people decide for themselves. We only try to present factual and well-sourced news.

Support objective journalism for a small contribution.